STEEred vs RING-mode Deep Brain Stimulation for Parkinson’s disease: STEERING trial
Objective: To evaluate whether directional STN DBS is more effective than ring-mode DBS in reducing PD motor symptoms, and to investigate if directional STN DBS…A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Phase IIa Trial to Evaluate the Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson’s Disease
Objective: To evaluate the efficacy of CVXL-0107 on motor symptoms and on levodopa-induced dyskinesia in advanced Parkinson’s disease (PD) patients. Background: CVXL-0107 is a glutamate…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia
Objective: This study was designed to assess the reproducibility of the amantadine anti-dyskinetic effect in the MPTP L-DOPA-Induced Dyskinesia (LID) macaque model for soundly defining…Levodopa Induced Orthostatic Hypotension in Parkinson’s Disease: A Single-Dose Response Study
Objective: To determine the effect and risk factors of a single dose levodopa induced OH in PD Background: Levodopa (LD) is widely recognised as the…Impulse control disorders could be accompanied by hypomanic state under intestinal levodopa infusion
Objective: To determine characteristics of parkinsonian patients under levodopa/carbidopa intestinal gel (LCIG) infusion who present impulse control disorders (ICDs). Background: ICDs may be induced by…Efficacy and security starting safinamide treatment with 100 mg/day in PD
Objective: Evaluating the efficacy and security starting safinamide treatment with 100 mg/day in PD Background: Dopaminergic treatment has been useful in PD. Other neurotransmission mechanisms…The course of Parkinson’s disease in patients with impaired carbohydrate metabolism
Objective: To study the state of lipid metabolism in PD patients with concomitant type 2diabetes (with different glucose tolerance and the effect of DA agonist…Patient and Provider Experiences and Attitudes toward Rytary
Objective: To survey Parkinson’s disease (PD) patients and providers about their experiences using Rytary, an oral extended release carbidopa/levodopa capsule (ER C/L). Background: ER C/L…Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and subdivided by their baseline OFF-time. Background: OPC,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.